2024
DOI: 10.4251/wjgo.v16.i6.2449
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

Tian-Qi An,
Hui Qiu,
Quan-Bo Zhou
et al.

Abstract: BACKGROUND Regorafenib (R) and fruquintinib (F) are the standard third-line regimens for colorectal cancer (CRC) according to the National Comprehensive Cancer Network guidelines, but both have limited efficacy. Several phase 2 trials have indicated that R or F combined with immune checkpoint inhibitors can reverse immunosuppression and achieve promising efficacy for microsatellite stable or proficient mismatch repair (MSS/pMMR ) CRC. Due to the lack of studies comparing the efficacy between F, R, F … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 33 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?